Biotrial today announced the continued strengthening of its medical team with a key appointment.
Didier Chassard, MD, will be working in close collaboration with Biotrial VP of Medical and Scientific Affairs, Alain Patat, MD. Dr. Patat, who himself joined Biotrial a few years ago from Wyeth Ayerst, commented, “ I am delighted to have such a well-known and respected international pharmacologist like Dr. Didier Chassard joining our team at Biotrial Paris. His 20 years of experience in early compound development will provide a significant contribution to the services we offer in Phase I, proof-of-concept studies, and many other areas.”
Dr. Chassard comes to Biotrial from SGS Paris Clinical Unit, (formerly ASTER-CEPHAC). Over the years, Dr. Chassard has had the opportunity to develop a strong and recognized expertise in the fields of women’s health, immunology, vaccinations, and endocrinology, to name a few.
Biotrial’s recent moves to strengthen its management team show the company’s focus on fortifying its a medical and operational excellence. The appointment of Dr. Chassard follows two other recent management team addition announcements. (See related October press releases.)
“I’m very pleased that Dr. Chassard has agreed to join our management team,” said Jean-Marc Gandon, Biotrial’s CEO. “I'm confident that his strong medical background, as well as his extensive leadership experience, will be instrumental in furthering the development of our Phase I-II activities. This newest executive appointment provides the foundation for our company’s next level of growth.”
Dr. Chassard, who holds his doctorate of medicine, also has a master’s degree in Pharmacology as well as computer science, statistics and epidemiology. He will be based in the Rueil Malmaison (suburb of Paris) Biotrial Phase I unit.